Open access, medical economics journal. Publishing leading studies that determine the cost-effectiveness of treatment and high-quality economic assessments
Joined April 2009
- Tweets2.2K
- Following766
- Followers1.4K
- Likes213
Pinned Tweet
Thrilled to share an article I co-authored with the Editors-in-Chief of Taylor & Francis's #healtheconomics journals! We surveyed 200+ #HEOR experts to identify key topics for 2026-27.
Read the article to find out the results and the EiC's insights๐ bit.ly/4ca6tTZ
Cell and #genetherapies offer durable, sometimes curative benefitsโbut high costs mean payers are still catching up on innovative payment strategies. Elias Pittos & Joe DePinto explore how payers are navigating these challenges. ๐
bit.ly/4zCjr6p
#HEOR
New paper tackles a key challenge in #healtheconomics: evaluating diagnostics & medical devices with limited comparative data. The authors use #bladdercancer as a case study to demonstrate novel methodological approaches.
Read the article in full here ๐ bit.ly/3TJy9ck
New research reveals the hidden workplace cost of #handeczema. Our study shows employers should prioritize early diagnosis & prevention of occupational hand eczema.
The impact is bigger than you think.
๐bit.ly/4hgD4cz
#HEOR #medicaleconomics
๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐๐ ๐๐ซ๐ญ๐ข๐๐ฅ๐
New #costeffectiveness analysis of xanomeline and trospium chloride as first-line #schizophrenia treatment from a US payer perspective.
Read more ๐ bit.ly/4ikCFrQ
Just in case you missed it! Our latest editorial features insights from Editors-in-Chief and readers on the #healtheconomics topics that will be important through 2026-27. Access the full editorial here ๐ bit.ly/4qH4o8a
#HEOR #medicaleconomics #pharmacoeconomics
Want to know which #HEOR topics will be important in 2026-27?
Read our latest editorial featuring expert opinions from the Editors-in-Chief and readers of Taylor & Francis's premier #healtheconomics journals๐ bit.ly/4qH4o8a
#pharmacoeconomics #AI #RWE #healthequity
Great example of how #graphicalabstracts amplify research impact!
This study examines the #healtheconomic impact of continuous vital sign monitoring. The visual summary makes findings accessible to #clinicians & #policymakers alike.
Check it out ๐ bit.ly/4fRoZRV
Journal of Medical Economics retweeted
New publication ๐ Real-world data, published in @JME_Journal, show outpatient vs inpatient cilta-cel administration reduced inpatient days in patients with R/R #MultipleMyeloma after โฅ4 prior LoT (2.4 vs 6.6 days PPPM; aIRR, 0.37; p < 0.001), with similar TFI, OS, CRS, and ICANS between cohorts.
Learn more: multiplemyelomahub.com/typesโฆ
#myeloma #mmsm #MedNews #MedEd
Journal of Medical Economics retweeted
New pub alert: Impact of Crohnโs perianal fistulas on healthcare resource utilization: a US chart review study tandfonline.com/doi/full/10.โฆ @JME_Journal
๐Substantial HCRU burden among patients with CD perianal fistulas, indicating an unmet need for effective management strategies that promote long-term fistula healing to ultimately support reduced patient burden and HCRU
Want to stay at the forefront of #healtheconomics? Our new monthly newsletter, ๐๐ฉ๐จ๐ญ๐ฅ๐ข๐ ๐ก๐ญ ๐จ๐ง ๐๐๐๐ฅ๐ญ๐ก ๐๐๐จ๐ง๐จ๐ฆ๐ข๐๐ฌ, delivers:
โ
Latest breakthrough studies
โ
Emerging research trends
โ
Expert insights shaping
๐invt.io/1lxbi1pqrjk
#pharmacoeconomics
Explore our latest review examining the impact of avoiding or delaying progression to metastatic castration-resistant #prostatecancer on quality of life, #mortality, and #economicoutcomes.
Click here to view the article in full ๐ bit.ly/49FgyIe
Journal of Medical Economics retweeted
After months of hard work, our SCD-PED economic cost model manuscript is now officially published in @JME_Journal. The burden of pediatric AKI is tremendous at nearly $400,000 per hospitalization.
But our SCD-PED is estimated to save almost $70,000 per hospitalization.
tandfonline.com/doi/full/10.โฆ
Our latest article examines ๐๐๐จ๐๐๐'s cost-effectiveness compared to other long-acting insulins, including glargine, detemir, and degludec. Discover the authors' findings by clicking the link ๐ bit.ly/4higT5r
#diabetes #costeffectiveness #healtheconomics #HEOR
๐จ Available now๐จ
Our latest review provides an essential insight into how #patientreportedoutcomemeasures can be included in #costeffectiveness models that inform #healthtechnologyassessments of non-oncology treatments.
Read it here ๐ bit.ly/4pnKUo5
๐ข ๐น๐๐๐๐๐๐๐๐
๐๐
๐๐๐๐
Discover the impact of treatment failure for #migraine on lost earnings among #triptan non-responders in the general population of #Denmark. Click the link for the full article ๐ bit.ly/4piFVoy
๐จ๐๐จ๐ฐ ๐จ๐ง๐ฅ๐ข๐ง๐๐จ
Our latest article evaluates the budgetary impact of pathways using cT1 versus SoC (liver biopsy or VCTE) to assign suspected #MASH patients to #resmetirom. Graphical abstract available below.
Click here for the full article ๐ bit.ly/4g3dLJQ
๐ข ๐ฑ๐๐๐ ๐๐๐๐๐๐๐๐๐
: Our latest article assesses the economic impact of #influenzavaccination across the #UAE and #Iraq. Click the link to access it in full.
๐bit.ly/3K2tz3u
Congratulations to the authorsโit was lovely to collaborate with you. #HEOR
๐ขRecommended read๐ข
"#Costeffectiveness of wastewater and environmental monitoring of #respiratorysyncytialvirus to guide universal infant immunoprophylaxis in #Canada"
Read the #plainlanguagesummary below or click here for the full article ๐ bit.ly/45BQlb3
#HEOR
We're excited to announce that our website now features a multimedia section showcasing our #videoabstracts. Access this content here๐ bit.ly/4oJik05
We have also expanded the extenders we offer to include #podcasts, and #videoarticles. Get in touch to find out more.